跳至主要内容
临床试验/NCT00276315
NCT00276315已完成3 期

A Phase III, Multicentre, Randomised, Assessor-blind, Parallel Groups, Reference Drug Controlled Study to Assess the Efficacy and Safety of a Single Administration, by Subcutaneous Injection of Dysport® for the Treatment of Hemifacial Spasm

Ipsen6 个研究点 分布在 1 个国家目标入组 332 人开始时间: 2005年12月1日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
Ipsen
入组人数
332
试验地点
6
主要终点
Percentage of responders (defined as Cohen scale improvement ≥ to 2 levels)

研究概览

简要总结

To compare the effectiveness and safety of Dysport® with the domestic Botulinum Toxin Type A (manufactured by Lanzhou Biologic Product Institute, P.R. China) for the treatment of hemifacial spasm.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient suffering from hemifacial spasm with at least 6 months duration (prior to visit 1)
  • Cohen scale ≥ to grade II

排除标准

  • Botulinum toxin type A treatment history within last 16 weeks prior to visit 1
  • Hemifacial spasm secondary to facial palsy
  • Previous alcohol or phenol injections or surgical therapy of the facial muscles
  • Requirement for botulinum toxin injection to site(s) of the body other than in this study

结局指标

主要结局

Percentage of responders (defined as Cohen scale improvement ≥ to 2 levels)

时间窗: At the end of week 4

次要结局

  • Percentage of responders (defined as Cohen scale improvement ≥ to 2 levels after medication)(At the end of week 1 and 12)
  • Improvement degree of spasm (Jankovic scale)(At the end of week 1, 4 and 12)
  • Assessment of efficacy by the subjects(At the end of week 1, 4 and 12)

研究者

发起方
Ipsen
申办方类型
Industry

研究点 (6)

Loading locations...

相似试验

Assessment of Effectiveness and Safety of Dysport®... | 临床试验